Characteristics of patients initiating teriparatide for the treatment of osteoporosis

被引:14
|
作者
Foster, S. A. [1 ]
Foley, K. A. [2 ]
Meadows, E. S. [1 ]
Johnston, J. A. [1 ]
Wang, S. [2 ]
Pohl, G. M. [1 ]
Long, S. R. [2 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Thomson Medstat, Ann Arbor, MI USA
关键词
bisphosphonates; demographics; osteoporosis; teriparatide; treatment;
D O I
10.1007/s00198-007-0455-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The demographic and clinical characteristics of patients initiating teriparatide were compared with those of patients initiating bisphosphonates for the treatment of osteoporosis. In these samples of commercially insured, Medicare, and Medicaid patients, patients initiating teriparatide were older, in poorer health, and appeared to have more severe osteoporosis than patients initiating bisphosphonates. Introduction The demographic and clinical characteristics of patients initiating teriparatide are compared with those of patients initiating bisphosphonates. Methods Beneficiaries (45 years and older) with at least one claim for teriparatide or a bisphosphonate from 2003 to 2005 and continuous enrollment in the previous 12 months and subsequent 6 months were identified from commercial, Medicare, and Medicaid administrative claims databases. Patients initiating teriparatide (commercial/Medicare (N=2,218); Medicaid (N=824)) were compared to patients initiating bisphosphonates (commercial/Medicare (N=97,570); Medicaid (N=77,526)) in terms of age, provider specialty, comorbidities, prior use of osteoporosis medications, fractures, BMD screening, health status, and resource utilization. Results Teriparatide patients were older and in poorer health than bisphosphonate patients. Approximately 38% of teriparatide patients in both groups had fractured in the pre-period compared to 16% of commercial/Medicare and 15% of Medicaid bisphosphonate patients. Teriparatide patients were more likely to have used osteoporosis medications in the pre-period (79.9% versus 32.1% (commercial/Medicare); 82.2% versus 19.6% (Medicaid)). Conclusions In these samples of patients, those initiating teriparatide differed from those initiating bisphosphonates. Teriparatide patients were older, in poorer health, and appeared to have more severe osteoporosis than bisphosphonate patients. Comparisons of treatment outcomes should take these differences in patient characteristics into consideration.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 50 条
  • [1] Characteristics of patients initiating teriparatide for the treatment of osteoporosis
    S. A. Foster
    K. A. Foley
    E. S. Meadows
    J. A. Johnston
    S. Wang
    G. M. Pohl
    S. R. Long
    [J]. Osteoporosis International, 2008, 19 : 373 - 377
  • [2] Indications to teriparatide treatment in patients with osteoporosis
    Rizzoli, Rene
    Kraenzlin, Marius
    Krieg, Marc-Antoine
    Mellinghoff, Hans-Ulrich
    Lamy, Olivier
    Lippuner, Kurt
    [J]. SWISS MEDICAL WEEKLY, 2011, 141
  • [3] Treatment of osteoporosis with Teriparatide in anorexia nervosa patients
    Toshie, Sasaki
    Takao, Kodama
    Chiemi, Nakamoto
    Yutaka, Suzuki
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2019, 88 : 130 - 130
  • [4] TREATMENT OF OSTEOPOROSIS WITH TERIPARATIDE IN ANOREXIA NERVOSA PATIENTS
    Sasaki, T.
    Kodama, T.
    Nakamoto, C.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S463 - S463
  • [5] Treatment of osteoporosis with Teriparatide in anorexia nervosa patients
    Sasaki, T.
    Kodama, T.
    Nakamoto, C.
    [J]. PSYCHOTHERAPY AND PSYCHOSOMATICS, 2013, 82 : 98 - 98
  • [6] TREATMENT OF OSTEOPOROSIS WITH TERIPARATIDE
    Alddafari, F.
    Tabti, E.
    Zetla, Z.
    Lounici, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (SUPPL 1) : S397 - S397
  • [7] Teriparatide in the treatment of osteoporosis
    Stroup, Jeffrey
    Kane, Michael P.
    Abu-Baker, Asim M.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (06) : 532 - 539
  • [8] Contributors to Secondary Osteoporosis in Patients Referred for Treatment with Teriparatide
    Anaforoglu, Inan
    Asik, Mehmet
    Ersoy, Kerem
    Kose, Mustafa
    Ayhan, Semiha
    Algun, Ekrem
    [J]. TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 17 (04) : 98 - 101
  • [9] Severe osteoporosis treatment with teriparatide
    Sarli, Marcelo A.
    Zanchetta, Maria B.
    Rey, Paula G.
    Spivacow, Francisco R.
    [J]. MEDICINA-BUENOS AIRES, 2013, 73 (05) : 428 - 432
  • [10] Teriparatide Treatment in Patients with Severe Osteoporosis Based on Romanian Protocol
    Carsote, Mara
    Valea, Ana
    Olaru, Maria
    Dumitrascu, Anda
    Dragomir, Adina
    Petris, Rodica
    Cocolos, Andra
    Petrova, Eugenia
    Dumitru, Nicoleta
    Ghemigian, Adina
    [J]. PROCEEDINGS OF THE 35TH BALKAN MEDICAL WEEK, 2018, : 112 - 116